Ensysce Biosciences

ENSCPhase 3

Ensysce Biosciences is pioneering a chemistry-first approach to prevent prescription drug abuse and overdose through its two proprietary technology platforms: TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance). The company's lead programs have received significant FDA designations, including Fast Track and Breakthrough Therapy, and it has secured approximately $12 million in non-dilutive grant funding from the National Institute on Drug Abuse. Ensysce is advancing its clinical pipeline with a focus on creating safer pain management therapies that could revolutionize the standard of care in a market with high unmet need.

Market Cap

$2.1M

Focus

Drug Delivery

ENSC · Stock Price

USD 0.584067.42 (-99.99%)

Historical price data

AI Company Overview

Technology Platform

Proprietary prodrug platforms TAAP™ (Trypsin-Activated Abuse Protection) for abuse deterrence and MPAR® (Multi-Pill Abuse Resistance) for overdose protection, using chemistry to control drug activation only in the gut.

Pipeline Snapshot

9 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
PF614 capsule + Placebo	Postoperative Pain, Acute	Phase 3
PF614 + Placebo	Acute Pain	Phase 2
PF614 + Naltrexone Hydrochloride + OxyContin	Healthy Volunteers	Phase 1
PF614 + Oxycodone extended-release + Naltrexone Hydrochloride	Healthy	Phase 1
Nafamostat Mesilate + Placebo	Pharmacokinetics	Phase 1

Opportunities

The primary growth opportunity is the successful development and commercialization of a first-in-class opioid that combines abuse deterrence with overdose protection, addressing a massive public health need.

The TAAP™ platform also offers potential expansion into other drug classes prone to abuse, such as stimulants and benzodiazepines.

Risk Factors

Key risks include clinical trial failure, regulatory hurdles despite Breakthrough designation, the need for substantial additional financing, and intense competition in the pain market requiring a potential commercial partnership for success.

Competitive Landscape

Ensysce competes with makers of abuse-deterrent formulation (ADF) opioids like Purdue and Collegium. Its differentiation is foundational, using chemistry (TAAP™/MPAR®) rather than physical barriers to prevent abuse and uniquely offering active overdose protection—a feature no approved product has.